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Kinetic basis of hyperhomocysteinemia in patients with chronic renal
failure. We investigated the elimination of total homocysteine (tHcy) from
plasma after peroral homocysteine (Hcy) loading in eight patients with
chronic renal failure. Data on bioavailability and distribution volume were
obtained from two patients and two healthy controls by performing both
intravenous and peroral Hey loading. Response to high-dose folic acid was
studied in six cases. Mean (SD) basal plasma tHcy was 27.4 (11.0) rM at
inclusion. The half-life and the area under the curve were about four times
higher, and clearance was reduced to 29.8% compared to controls.
High-dose folic acid had no influence on half-life for tHey, but the basal
tHcy level declined by 26.8%. The reduction in tHey was particularly
pronounced in three patients with low-normal serum folate, and the
enhanced methionine response to Hey loading after folic acid suggested
improved Hey remethylation in tissues. In conclusion, patients with renal
failure had markedly reduced clearance of tHey from plasma, which
probably accounts for their hyperhomocysteinemia. High-dose folic acid
reduces fasting tHey by improving tissue Hey remethylation without
affecting the low renal clearance of tHey.
A large number of clinical investigations [1—41, including three
studies with a prospective design [2—4], demonstrate that elevated
levels of the sulphur amino acid homocysteine (Hey) in plasma is
a strong and independent risk factor for cardiovascular disease. In
addition to genetic defects or polymorphisms involving Hey-
metabolizing enzymes, several acquired conditions and disease
states cause elevated total homocysteine (tHey), that is, hyperho-
mocysteinemia. The relation between tHey and folate and cobal-
amin status has been studied in great detail [5], and tHey has been
shown to be an early and sensitive marker of impaired function of
these two vitamins [6]. The hyperhomocysteinemia in folate or
cobalamin deficiencies can be explained by impaired function of
the enzyme methionine synthase (5-methyltetrahydrofolate-
homocysteine methyltransferase, EC 2.1.1.13), which requires
5-methyltetrahydrofolate as methyldonor and cobalamin as co-
factor in a reaction where Hey is remethylated to methionine [7].
Plasma tHey is also increased in renal failure and is closely related
to serum creatinine [8], but the mechanism behind this relation-
ship is debated. Large amounts of Hey is formed in conjunction
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with creatine/creatinine synthesis [9], and recent data suggest that
glomerular filtration rate (GFR) is a strong determinant of the
plasma tHey level [10]. Notably, urinary Hey excretion is normally
not a route of Hey disposal, since only 0.25 jimol/hr of Hey is
excreted unchanged in the urine [11], indicating that more than
99% of filtered Hey is subjected to tubular reabsorption [12]. A
recent study in the rat suggests that substantial metabolism of Hey
may take place in the kidney [13].
The hyperhomocysteinemia in folate/cobalamin deficiency as
well as in renal failure is a steady state condition characterized by
either increased net transport of Hey from tissue to plasma and/or
decreased Hey elimination from the central compartment. We
recently determined the half-life (T112) for tHey in folate and
eobalamin-defieient subjects after peroral ingestion of Hey [12],
and observed that it was equal to that found in healthy subjects
[14]. This observation together with in vitro experiments with
cultured cells [15] suggest that the elevation of tHey in folate/
cobalamin deficiency is related to increased net Hey efflux from
tissues to plasma.
In the present study, we used the Hey loading test [14] to
determine the kinetics of tHey in patients with chronic renal
failure. The investigation was performed before and after supple-
mentation with high-dose folic acid, which significantly reduces
fasting tHey in most patients even in the absence of overt folate
deficiency [16, 17]. This study shows that the increased tHey level
in renal failure probably is due to a marked reduction of tHey
clearance from plasma, and that clearance is not enhanced by folie
acid.
METHODS
Subjects
Eight patients, three females and five males, with a mean SD
age of 51 12 years, with chronic renal failure (mean SD serum
creatinine, 477 113 .tM) were recruited from the Nephrological
Outpatient Clinic at Haukeland University Hospital, Bergen,
Norway. Mean SD GFR estimated from serum creatinine, age,
sex and body wt [18, 19] was 18 6 ml/min. Patient characteristics
are shown in Tables 1 and 2.
As controls, we used historical data [14] and one additional
healthy male subject, aged 26 years, who received a peroral and
intravenous Hey load.
All individuals had given their written informed consent to the
study, which had approval by the ethical committee of Western
Norway.
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Table 1. Characteristics of patients before first and second homocysteine loading
Patient Sex
Age
years
Weight
kg
MTHFR
genotype
Hemoglobin
glliter
First Second
Crea
First
tinine
pM
Second
G
ml!
First
FR
mm
Second
S-cob
First
alamin
pM
Second
S-f
n
First
olate
M
Second
E-f
n
First
olate
M
Second
Group 1°
1 M 63 83 CC 133 136 359 395 22 20 373 407 11.9 11.3 801 746
2 F 57 57 CT 129 130 552 454 9 11 668 638 6.7 8.5 432 442
Group II
3 M 43 102 TI' 117 121 582 663 21 18 592 626 5.2 45.0 738 966
4 M 62 82 CC 88 100 418 551 19 14 457 421 12.5 45.0 752 2361
5 F 52 71 TI' 113 106 625 623 10 11 417 332 14.7 45.0 718 2012
6 M 46 75 TI' 100 119 344 327 25 27 200 268 7.5 43.5 481 1760
7 M 55 75 CT 101 96 556 626 14 13 498 609 13.7 45.0 654 1064
8 F 27 73 TI' 139 118 376 436 23 20 499 448 4.7 35.3 634 1495
Mean group II 110 110 484 538 19 17 444 451 9.7 43.1 663 1610
SD 18 11 119 131 6 6 133 144 4.4 3.9 101 543
Abbreviations are: MTHFR, methylenetetrahydrofolate reductase; GFR, glomerular filtration rate; CC, CT and TI' refer to normal homozygous,
mutant heterozygous and mutant homozygous genotype, respectively; S-cobalamin, serum cobalamin; S-folate, serum folate; E-folate, erythrocyte folate.
a Group I consists of two patients undergoing one peroral and one intravenous homocysteine loading, and group II comprises patients receiving two
peroral loadings, one before and one after high-dose folic acid supplementation.
Protocol
Plasma tHcy kinetics and folic acid supplementation. The partic-
ipants had a light breakfast one to two hours before the Hcy
loading. Six subjects received two peroral Hcy loadings (65
.tmol/kg body wt). The second load was performed after at least
10 days (range 10 to 47 days) of folic acid supplementation (5
mg/day). Assessment of bioavailability and distribution volume
(Vd) was performed in two patients with chronic renal failure and
in two healthy controls. They were first subjected to one peroral
load, and after about three weeks, they received an intravenous
load by injecting the same Hcy dose: 65 imol/kg in the controls
and 32.5 mol/kg in the renal patients. The lower dose in the two
patients was chosen to avoid prolonged exposure to high tHcy
levels.
The Hcy solution was prepared immediately before administra-
tion [14], and was swallowed or injected in less than two minutes.
For at least two hours after the administration, the person
refrained from intake of food but was allowed to drink water and
apple cider.
Blood and urine collections. Before administration of Hcy, a
blood sample was collected for the determination of hemoglobin,
the C677T mutation in the methylenetetrahydrofolate reductase
(MTHFR) gene, and serum/plasma levels of creatinine, folate,
cobalamin, tHcy, free Hcy (fHcy), total cysteine (tCys), and
methionine (Tables 1 and 2). A total of 13 blood samples were
routinely collected, that is, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24,
48 and 72 hours after the administration of Hcy. After intravenous
injection, more frequent sampling was done during the first 0.5
hours. During the first 8 to 12 hours, blood samples were collected
through a 1.7 mm cannula inserted into a cubital vein. Later,
blood samples were obtained by venous puncture. In all patients,
urine was collected in fractions for 24 hours.
Laboratory procedures
Whole blood was drawn into evacuated tubes without an
additive (for preparation of serum) or containing EDTA as the
anticoagulant (for preparation of plasma). Blood containing
EDTA was immediately transferred to 1.5 ml vials, which were
centrifuged at 13,000 X g for 0.5 minutes. This procedure allowed
separation of the plasma fraction from the blood cells within three
minutes. One milliliter of plasma was immediately deproteinized
by adding 100 pA of 2 M sulfosalisylic acid, mixed and centrifuged,
and the acid supernatant collected. Plasma and the acid superna-
tant were stored at —20°C until analyses of total and free plasma
aminothiols and methionine. Whole blood without additives was
allowed to coagulate for 0.5 to 1 hour at room temperature. Then,
the tubes were centrifuged at 1,000 X g for 10 minutes, and the
serum fraction transferred to storage vials.
The concentrations of tHey and tCys in untreated plasma, fHcy
in acid-precipitated plasma and Hcy in urine were determined by
a modification [20] of an automated procedure developed for the
determination of tHcy [21]. The between-day coefficient of vari-
ation was about 3%. Plasma methionine was determined with an
assay based on derivatization with o-phthaldialdehyde and fluo-
rescence detection [22]. Serum cobalamin was determined with a
niicroparticle enzyme intrinsic factor assay run on an IMx system
from Abbott (Abbott Park, IL, USA), and serum folate was
assayed using the Quantaphase folate radioassay produced by Bio
Rad (Hercules, CA, USA). The procedure for detection of the
C677T mutation in the methylenetetrahydrofolate reductase gene
was based on PCR amplification, restriction cleavage and separa-
tion of the DNA fragments by capillary electrophoresis [23].
Kinetic parameters
Kinetic parameters were calculated from the increase in tHcy
after Hcy administration, using the parts of the plasma curves with
essentially no interference from the basal tHcy level. Two proce-
dures were used for the determination of the kinetic constants. (1)
The elimination rate constant was obtained by linear regression of
the terminal, linear part of the log-transformed concentration
versus time curve. Because of different kinetics in renal patients
versus healthy subjects [14], this was in the time interval between
three hours and 24 hours for the patients and between two hours
and six hours for the healthy controls. The kinetic parameters
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Table 2. Plasma and urinary levels of homocysteine, cysteine and methionine before first and second homocysteine loading
Plasma
Urina
pm
First
ry Hcy
ol/hr
SecondPatient
tHcy p.M
First Second
fHcy pM
First Second
fHcy/tHcy
First Second
tCys pM
First Second
Meth
First
ionine
pM
Second
Group a
1 23.5 22.2 6.4 5.9 0.27 0.27 350.2 331.2 27.2 26.7 0.4 0.6
2 50.2 46.9 14.5 14.3 0.29 0.30 316.5 342.8 15.8 18.7 4.8 3.5
Group II
3 27.7 17.2 7.8 4.9 0.28 0.28 334.6 334.8 31.1 39.4 2.6 1.1
4 20.7 20.8 5.9 5.5 0.28 0.27 377.1 323.7 39.0 32.3 0.7 1.4
5 24.6 26.0 6.4 7.1 0.26 0.27 424.3 468.7 25.7 18.4 0.8 0.6
6 35.6 15.2 9.4 3.4 0.26 0.22 320.5 245.6 27.9 20.3 0.5 0.4
7 22.2 18.3 6.9 5.7 0.31 0.31 391.1 409.2 26.8 22.3 2.2 5.0
8 14.7 9.0 3.9 2.4 0.27 0.27 227.9 266.6 28.6 15.7 1.7 0.7
Mean group II 24.3 17.8 6.7 4.8 0.28 0.27 345.9 341.5 29.9 24.7 1.4 1.5
SD 7.1 5.7 1.8 1.7 0.02 0.03 69.1 84.8 4.8 9.2 0.9 1.7
Abbreviations are: tHey, total homocysteine; fHcy, free homocysteine; tCys, total cysteine; Hey, homocysteine.
a Group I is two patients undergoing one peroral and one intravenous homocysteine loading, and group II comprises patients receiving two peroral
loadings, one before and one after high-dose folic acid supplementation.
were calculated using KaleidaGraph, version 2.1.3 for Macintosh
(Synergy Software, Reading, PA, USA). (2) The time course for
tHey was also analyzed by the program PCNONLIN version 4.0
(Statistical Consultants Inc., Lexington, KY, USA) based on the
Akaike's information criterion [24] for the best curve fit. T112
obtained by these two methods differed by less than 10% in most
patients.
The elimination of tHcy after peroral loading obeys first order
kinetics and is consistent with a one-compartment, open pharma-
cokinetic model. T112 was obtained by the equations [25]:
C=Ce (Eq.1)
T1 = 1n2/k
where C is the plasma concentration at time t, C0 the extrapolated
plasma concentration at t = 0, and k the rate constant of the
elimination.
AUC0>OO is the area under the plasma concentration-time
curve from zero to infinite time measured by the trapezoidal rule
[26]. Because plasma tHcy returned to basal level in most patients
within 72 hours, AUCO72hr was taken as identical to AUC0>O.S.
In the subjects having one intravenous and one peroral Hey
loading, we also calculated bioavailability, F, distribution volume,
V, and clearance, Cl [25]:
F = AUC1/AUC
CI = F D/[AUC0]
where D is the dose of Hcy.
was calculated by the area method, which provides the most
correct estimate after an intravenous injection [27]:
Vd = F D/[k AUGJ>,J = Cl/k
Assuming that the kinetics are independent of plasma concen-
tration [141, we can determine the rate of Hey influx into the
plasma compartment (R0) from the equation:
C = R0/Cl
where refers to the steady state (basal) concentration of
plasma tHey.
Statistical methods
The results are given as mean and SD or range. Comparison of
paired data were performed using the Wilcoxon signed rank test,
and unpaired values using the Mann-Whitney U-test.
RESULTS
Patient characteristics
The patient characteristics and various biochemical parameters
i 2 are listed in Tables 1 and 2. All renal failure patients had
markedly elevated serum creatinine (> 325 .tM), and GFR was
reduced. The levels of serum folate, serum cobalamin and plasma
methionine were normal, whereas plasma tHey was elevated
(mean SD) to 27.4 11.0 LM. The mean SD plasma fHcy was
7.7 3.2 p.M, which is about twice the level found in normal
controls [28], and the plasma tCys was 342.8 59.4 /.LM, which is
higher than in 329 healthy controls (281.9 33.8 j.tM) randomly
selected from the Hordaland Homocysteine Study [29].
Bioavailability, Vd and clearance
Interpretation of tHey values during fasting and after Hey
loading in renal failure patients requires data on bioavailability
and Vd of Hey. Therefore, we performed both a peroral and
intravenous Hey load in two renal patients and compared the
results with two healthy controls. The peroral and intravenous
plasma tHey curves for these four subjects are depicted in Figure
1, and the kinetic parameters are summarized in Table 3. Inde-
pendent of the route of administration, AUC (corrected for dose)
was high and the T172 was longer (about 4-fold) in the renal
patients than in the healthy subjects. Notably, bioavailability (0.64
and 0.88) and Vd (0.42 and 0.45 liter/kg) in two patients with renal
failure were similar to these parameters in healthy subjects
(bioavailability = 0.70 and 0.53; = 0.42 and 0.35 liter/kg).
Based on these values (Table 3), mean plasma tHey clearances
(Eq. 6) were calculated (equation 4) to 104 mI/mm in the controls and 31
(Eq. 3)
(Eq. 4)
(Eq. 5)
80
60
Fig. 1. Bioavailability of peroral homocysteine
determined from plasma tHey curves after
peroral (0) and intravenous (•) homocysteine
loading of two healthy controls (A, B) and two
patients with renal failure (C, D). The program
PCNONLIN was used for curve fitting. The
area under the plasma concentration curves
after peroral (AUC,) and intravenous
administration of homocysteine (AUCV) were
calculated by the trapezoidal rule, and the
bioavailability, F, was determined as the ratio
AUC 0IAUC . The homocysteine dose was 650 12 24 36 48 0 12 24 36 48
.tmo1kg in the healthy controls whereas the
dose was reduced to 32.5 rmol/kg in the renalTime (h) patients.
Table 3. Kinetics of plasma total homocysteine as determined by peroral and intravenous homocysteine loadinga in two patients and two controls
Cmax MM Tmax hr AUCO4Shr
p.o. iv.
T112
p.o.
hr
i.v. Bioavailability
Vd
liter/kg
Clearance
mI/mmSubject p.o.
Patient 1 45.0 2.0 800 1247 12.0 11.2 0.64 0.42 36
Patient 2 51.1 2.0 1069 1219 [5.2 11.6 0.88 0.45 25
Control 1 67.9 0.5 440 626 3.4 2.8 0.70 0.42 130
Control 2 70.2 1.0 442 827 3.3 3.1 0.53 0.35 79
Abbreviations are: Cm, maximal increase in plasma total homocysteine (tHey); Tm, time to reach Cm; AUCO.4shr; area under the plasma
concentration curve for tHey in the interval 0 to 48 hours; T112, elimination half-life for tHcy; Vd, distribution volume; p.o., peroral administration; i.v.,
intravenous administration.
a The homocysteine dose was 32.5 1tmol/kg in the patients and 65 mol/kg in the controls.
Plasma tHcy kinetics before and after folic acid
supplementation
The plasma curves for tHcy after peroral Hey loading in
patients with chronic renal failure were described in terms of peak
A Control 1
F=0.70
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C Patient 1
F=0.64
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F=0.88
40
20
0
ml/min in the two renal failure patients; that is, a reduction to concentration (Cm), time to reach peak concentration (Tm),
29.8% of the value observed in healthy controls. T112 and AUC. AUC was a measure of the systemic exposure to
Hey in the individual. The Hey loading was performed in six renal
patients before and after folic acid supplementation, and the
results are summarized in Table 4. In patients not supplemented
with folic acid, T112 (mean SD = 12.7 2.8 hr) and AUC
(2137 574 tLM hr) were about four times higher than in healthy
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Table 4. Kinetics of total plasma homocysteine after peroral homocysteine loadinga
Subject
Cma
First Second First
Tmax hr
Second
AUC07
First
Zhr p.ihr
Second First
T112 hr
Second
Patients, group II
3
4
5
6
7
8
134.7
102.2
134.2
96.7
98.1
64.9
131.0
95.9
134.0
78.9
102.7
50.1
1.0
2.0
1.5
3.0
2.0
2.0
1.5
2.0
2.0
2.0
0.5
3.0
2129
2317
2668
2715
1796
1197
1964
2355
3166
1949
1826
1021
11.6
13.0
11.1
18.1
12.3
10.3
13.9
12.6
13.7
16.7
12.3
12.8
Mean
so
105.1
26.3
98.8
31.8
1.9
0.7
1.8
0.8
2137
574
2047
702
12.7
2.8
13.7
1.6
Historical controlsb
Mean
SD
57.4
9.9
1.0
0.3
416
41
3.7
0.8
Abbreviations are: Cmax, maximal increase in plasma total homocysteine (tHey); Tm, time to reach Cmax AUCO72hr, area under the plasma
concentration curve for tHey from 0 to 72 hours; T112, elimination half-life for tHey.
a The homocysteine dose was 65 jsmol/kg.
b Data are from reference 14.
controls [14]. After supplementation, mean fasting tHey was
decreased by 26.8% (from mean SD of 24.3 7.1 .tM to 17.8
5.7 ELM, P = 0.22), but this tHey response was largely confined to
three patients homozygous for the C677T mutation and with
serum folate in the low normal range (< 7.5 nM; Table 1). Despite
a reduction in their basal tHcy and a reduced Cmax in two out of
three subjects, there was no significant change of T112 or AUC for
tHey (Table 4).
Assuming that bioavailability is 0.6, the mean SD tHcy
clearance in the six renal patients was 26 8 mi/mm and 28 12
mi/mm before and after folic acid, respectively, and 101 15
mi/mm in healthy controls [14].
Urinary Hey excretion
Urinary Hcy excretion was 1.4 0.9 .tmol/hr before and 1.5
1.7 j.tmol/hr after folic acid supplementation. After the first
peroral Hey loading, the fraction of the Hey dose excreted
unchanged into the urine was 2.5 1.6% (mean SD) during the
first 24 hours, and this was essentially unchanged after folic acid
supplementation.
Methionine response
We have previously found that in healthy subjects, plasma
methionine increases within the first two hours by about 10 xM in
response to a peroral Hey dose of 65 .tmoi/kg [14]. In contrast,
folate/cobalamin—deficient subjects have a markedly reduced
plasma methionine response [121. In three renal failure patients
with normal serum folate, the methionine response was larger
(maximal increase in plasma methionine of 18.2, 19.6 and 20.1
M) than the average response in historical controls [14]. In three
renal patients with serum folate < 7.5 nM, we observed a relatively
small increase in post-load methionine (maximal response, —4.3,
8.0 and 8.2 p.M), which became markedly increased after folic acid
therapy (Fig. 2).
DISCUSSION
We have used a Hey loading test to investigate the kinetic basis
of hyperhomoeysteinemia consistently reported in patients with
renal failure [30—33]. Notable findings were values for AUC and
T112 that were about four times higher (Table 4) than the values
previously reported for healthy controls [14] and patients with
folate or cobalamin deficiency [12]. To estimate clearance, we
required the data on bioavailability and Vd that were obtained by
peroral and intravenous Hey loading in two patients and two
controls. The small difference in these parameters between renal
patients and healthy subjects (< 20%) cannot explain the mark-
edly prolonged T112 in renal patients. Assuming that bioavailabil-
ity is 0.6 and Vd is similar for patients and healthy subjects, the
tHey clearance was calculated to be 26 8 mi/mm, which is only
25.7% of the clearance in healthy controls (101 15 ml/min) [14].
This leads to the key message of this report: that impaired renal
function causes a substantial increase in T112 for tHey explained by
a reduction in total body clearance.
Chronic elevated tHey represents a steady state concentration
(C) explained by either enhanced release of Hey from tissues to
plasma and/or decreased total clearance. We have previously
demonstrated that hyperhomoeysteinemia in folate and cobal-
amin deficiency is associated with normal tHey clearance, and that
the elevated tHey level probably is related to increased net Hey
influx into plasma, estimated to about 650 imol/hr in one subject
with cobalamin deficiency [12]. Using equation 6, we determined
that the average net influx (R0) of Hey into plasma (about 55
mol/hr) was the same in two healthy controls and the two
patients with renal failure. These calculations demonstrate that
the markedly reduced tHey clearance in renal patients accounts
for the elevated tHey level.
The mechanism behind the pronounced reduction of tHey
clearance in renal failure is conjectural. Renal failure seems to
have marked and complex effects on amino acid metabolism, and
total clearance of some amino acids are increased while that of
others are decreased [34], which has partly been attributed to
altered hepatic metabolism [35]. However, the changes in plasma
level or total clearance of most amino acids in chronic renal
failure are usually less than 35% [34, 35], and the marked
hyperhomocysteinemia and reduction in clearance by 70% em-
phasize the importance of kidney function for Hey homeostasis.
The only known effective tHey reducing therapy in subjects with
renal failure is peroral high doses of folie acid, either alone or in
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Fig. 2. Plasma tHcy curves and methionine
response after peroral homocysteine loading
(65 tmol/kg) in six renal patients before (0)
and after (•) folic acid supplementation for at
least 10 days. Upper panel shows the mean
increase in plasma tHey concentration with SD
given as bars, and the data points obeying first
order kinetics are replotted in a
semilogarithmic graph in the inset. Lower left
panel shows plasma methionine in three
patients with low serum folate and whose basal
tHcy levels were markedly reduced (—37.9%,
—38.8% and —57.3%) following folic acid
administration. Lower right panel shows the
methionine response in three patients with
essentially no change (+1.0%, —17.5% and
+5.7%) in fasting tHcy after folic acid. For
comparison, the tHcy curve (A and inset) and
the methionine response (B and C) after
homocysteine loading of 13 healthy historical
control [14] are given. These data are depicted
as thin lines (mean) with a shaded area (SD).
combination with vitamin B12 and B6 [16, 17, 36—38]. We con-
firmed that there was a reduction in the tHcy level upon folic acid
supplementation (Table 2), but the reduction was confined to
three renal patients with low-normal serum folate. The increased
methionine response suggests improved Hcy remethylation in
these patients. Notably, as in folate and cobalamin deficiency [12],
folic acid did not influence tHcy clearance (Fig. 2).
We found that in the renal patients the basal urinary excretion
of Hey was 1.4 j.tmol/hr, which is substantially higher than in
about 3 /.LM [111, the normal kidneys filter about 20 mol!hr of
Hcy, indicating that only 1% is excreted. The average GFR in the
patients was 19 mi/mm (Table 1), and the fHcy level was about 8
jLM, indicating that about 10 molThr of Hey will be filtered. This
suggests that about 85% of the filtered Hey is subjected to tubular
reabsorption, compared to 99% under normal conditions [12].
However, both in healthy subjects and in the patients with renal
failure, the amount of Hey excreted in the urine is a minor fraction
(<3%) of the estimated supply of Hey to plasma (55 j.Lmollhr).
healthy subjects (0.25 jmol/h) [11]. With a fHcy concentration of The mechanism for hyperhomocysteinemia in renal failure is
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debated in the literature [33, 39]. A preliminary report suggests
that there is minimal renal extraction of Hcy in humans [40]. In
contrast, Bostom et a! [13] have shown that there is a substantial
net uptake of Hcy in the normal rat kidney. Our kinetic data show
that tHcy clearance is markedly reduced in renal failure, and are
in line with the data reported by Bostom et al [13] pointing to the
kidney as the major site for elimination of Hcy from plasma.
Conclusion
We have demonstrated that chronic renal failure is associated
with a marked (70%) reduction of tHcy clearance, which accounts
for the hyperhomocysteinemia in these patients. Experimental
and kinetic evidence shows that low clearance is related to
impaired uptake and metabolism of Hey in the kidney. If this is
the case, our data suggest that the kidneys are responsible for at
least 70% of plasma tHcy clearance under physiological condi-
tions. Folic acid supplementation is an effective means to reduce
fasting tHcy in renal failure. However, folic acid enhances Hcy
remethylation in tissues, thereby lowering Hcy efflux into the
plasma compartment, but does not affect total body clearance of
tHcy that remains low in renal patients.
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APPENDIX
Abbreviations used in this paper are: Hcy, homocysteine; tHey, total
homocysteine; GFR, glomerular filtration rate; Vd, distribution volume;
fHcy, free homocysteine; tCys, total cysteine; AUC, area under the curve.
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